What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical evidence from the KEYNOTE-716 trial demonstrates a clear clinical advantage for pembrolizumab, showing significant improvement in recurrence-free survival and distant metastasis-free survival compared to placebo. However, overall survival data remains immature, which prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for pembrolizumab are likely within NICE’s acceptable range, with ICERs around £20,000 per QALY gained. Despite some uncertainties in the economic model, the overall assessment supports its cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
While the document does not provide extensive HRQoL data, the evidence suggests that pembrolizumab may improve quality of life by reducing the fear of recurrence in patients with resected melanoma. However, the potential for severe adverse effects may offset some of these benefits.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Pembrolizumab has a very good safety profile, with manageable adverse events. The committee noted that while about 10% of patients may experience permanent adverse effects, the overall tolerability is considered acceptable.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against placebo in a well-designed Phase 3 trial, which is appropriate for assessing its efficacy. The use of placebo as a comparator is justified given the lack of available adjuvant treatments for this patient population.
Is the population defined the way payers need it? — Patient Population and Subgroups
The KEYNOTE-716 trial population is considered representative of the Healthcare patient population, with adequate subgroup analyses. However, the trial’s demographic skew towards white participants may limit generalizability to other ethnic groups.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Pembrolizumab can be integrated into existing treatment pathways with minor adjustments, as clinicians are already familiar with its use in later-stage melanoma treatments. This facilitates its adoption in clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of pembrolizumab are manageable, with the potential for cost savings through reduced recurrence rates. The economic model indicates that the treatment is likely to be resource-efficient.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a robust Phase 3 trial with low bias risk. However, the immaturity of overall survival data introduces some uncertainty, preventing a higher rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding overall survival and subsequent treatment pathways, the context of unmet need and the potential benefits of pembrolizumab mitigate some of these concerns.
